Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

Participants with heFH who had completed one of the four parent studies (EFC12492, R727-CL-1112, EFC12732 and LTS11717).

Significant protocol deviation in the parent study; Any permanent treatment discontinuation from the parent study.
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Open Label Study of Long Term Safety Evaluation of Alirocumab